- Home
- PSF vs GOSS Comparison
PSF vs GOSS Comparison
Compare PSF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- GOSS
- Stock Information
- Founded
- PSF 2010
- GOSS 2015
- Country
- PSF United States
- GOSS United States
- Employees
- PSF N/A
- GOSS N/A
- Industry
- PSF Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- GOSS Health Care
- Exchange
- PSF Nasdaq
- GOSS Nasdaq
- Market Cap
- PSF 242.7M
- GOSS 212.9M
- IPO Year
- PSF N/A
- GOSS 2019
- Fundamental
- Price
- PSF $19.70
- GOSS $0.81
- Analyst Decision
- PSF
- GOSS Strong Buy
- Analyst Count
- PSF 0
- GOSS 5
- Target Price
- PSF N/A
- GOSS $9.20
- AVG Volume (30 Days)
- PSF 25.0K
- GOSS 2.3M
- Earning Date
- PSF 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- PSF 7.69%
- GOSS N/A
- EPS Growth
- PSF N/A
- GOSS N/A
- EPS
- PSF N/A
- GOSS N/A
- Revenue
- PSF N/A
- GOSS $105,322,000.00
- Revenue This Year
- PSF N/A
- GOSS N/A
- Revenue Next Year
- PSF N/A
- GOSS N/A
- P/E Ratio
- PSF N/A
- GOSS N/A
- Revenue Growth
- PSF N/A
- GOSS N/A
- 52 Week Low
- PSF $16.00
- GOSS $0.50
- 52 Week High
- PSF $20.19
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- PSF 21.41
- GOSS 49.87
- Support Level
- PSF $20.32
- GOSS $0.76
- Resistance Level
- PSF $20.24
- GOSS $0.88
- Average True Range (ATR)
- PSF 0.17
- GOSS 0.08
- MACD
- PSF -0.08
- GOSS 0.01
- Stochastic Oscillator
- PSF 0.00
- GOSS 30.48
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.